Analysis
Novo Nordisk Slides Despite Raised Guidance: What Worried Investors?
Novo Nordisk raised its 2026 outlook but shares fell as Wegovy pill sales, CagriSema data and competition from Eli Lilly disappointed investors.
FINANCEMARKETS.INFO